![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.indianpharmapost.com/news/themis-medicare-posts-q1-fy25-consolidated-pat-higher-at-rs-2468-cr-15946
https://www.indianpharmapost.com/news/themis-medicare-launches-lenzetto-for-treatment-of-menopausal-symptoms-13540
https://www.indianpharmapost.com/news/themis-medicare-revenue-down-1526-profit-down-776-13273
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/themis-medi-bets-big-on-antiviral-drug-for-covid/articleshow/92812513.cms
https://health.economictimes.indiatimes.com/news/pharma/dcgi-approved-themis-medicares-viralex[…]inst-covid-19-viral-respiratory-infections/92727299
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/themis-gets-drug-controllers-nod-to-launch-inosine-pranobex-a-novel-medicine-to-treat-covid19-a-viral-infection/articleshow/90156806.cms
https://www.fiercepharma.com/pharma/themis-eyes-phase-3-for-chikungunya-vaccine-after-passing-midstage-test
https://www.fiercepharma.com/pharma/themis-eyes-phase-3-for-chikungunya-vaccine-after-passing-midstage-test
http://www.pharmabiz.com/NewsDetails.aspx?aid=110483&sid=1